Is JP Morgan Asset Management (CLONE) a Scam?

At FXCanary, our safety assessments are built on a foundation of verifiable, public-record evidence: regulatory licences, corporate registrations, and the broker's own published terms. We cross-check every claim against official registers and treat the absence of a licence as a material fact, not a footnote. For a broker with no independent user reviews, this documentary trail is the only reliable starting point, and it is often the most telling one.

Our Scam Risk Score is a composite measure that weighs regulatory oversight, corporate transparency, and operational history. A score of 55/100 — which we class as 'Elevated' — signals that a trader should proceed with extreme caution. In this case, the score is driven by two specific flags: no verified regulatory licence on file, and no verifiable website or social-media presence that we can independently confirm. Neither flag is a verdict of fraud on its own, but together they describe an entity that is exceptionally difficult to hold accountable.

The most consequential finding in our records is that JP Morgan Asset Management (CLONE) holds no regulatory licence whatsoever. We do not state a licence number because none is published in our records — the licence count is zero. This means the broker is not authorised by any financial regulator we can identify, whether a tier-one authority like the FCA, CySEC, or ASIC, or even a less stringent offshore body.

For a client, this has immediate practical consequences. There is no independent body to which you can escalate a dispute, no conduct-of-business rules the firm is legally bound to follow, and no requirement to segregate client funds from the firm's own operating capital. In the event of a dispute or a collapse, your recourse is limited to whatever the broker itself chooses to offer — and with no licence, there is no external pressure to offer anything at all.

Regulated brokers are typically required to hold client money in segregated accounts, ring-fenced from their own funds, and to participate in a compensation scheme that covers a portion of client losses if the firm fails. In the EU and UK, for example, schemes like the FSCS or the ICF protect eligible clients up to a set ceiling, and negative-balance protection shields retail traders from owing more than they deposited. None of these protections can be assumed here.

Because JP Morgan Asset Management (CLONE) is unlicensed, there is no legal obligation to segregate client funds, no compensation scheme to fall back on, and no requirement to offer negative-balance protection. If the broker holds client money in its own accounts, a client is effectively an unsecured creditor. We cannot confirm how client funds are handled because the firm publishes no verifiable terms — and that lack of transparency is itself a red flag.

The name 'JP Morgan Asset Management' is a deliberate echo of one of the world's most recognised financial institutions, J.P. Morgan. This is not a coincidence.

Clone firms routinely adopt names, domains, and branding that mimic legitimate entities to borrow credibility they have not earned. The domain jpmorgan-income.com is not the official domain of J.P. Morgan, and we have found no evidence linking this entity to the real bank.

Our records list zero confirmed impersonator sites for this broker, but that is a narrow finding: it means we have not catalogued other domains that copy this specific clone. It does not reduce the impersonation risk inherent in the name itself. A trader searching for 'JP Morgan Asset Management' could easily land on this site believing it is the genuine article, and the onus is on the trader to verify the domain and the regulator before parting with any money.

We must be plain about the limits of our research. There are no independent user reviews of this broker, no verified social-media presence, and no regulatory filings that we can inspect. The country of registration is unknown, and the firm's founding date is not on file. This is an unusually thin information set, even for a newly established broker.

In FXCanary's assessment, this absence of verifiable information is itself part of the safety picture. A legitimate broker, however small, typically leaves some trace: a company registry entry, a financial regulator's authorisation list, or at least a coherent website with a physical address and named principals. Here, we have none of that. The only reliable facts are the name, the domain, and the absence of a licence — and none of those inspire confidence.

If you are considering any engagement with JP Morgan Asset Management (CLONE), the first step is to verify the domain. The genuine J.P. Morgan operates through jpmorgan.com and its regional variants, not jpmorgan-income.com. A simple check of the official website and a search of the relevant regulator's register would reveal that this entity is not authorised.

Second, treat any request for funds with extreme suspicion. Unlicensed brokers often demand payment via wire transfer, cryptocurrency, or other irreversible methods, and they may pressure you to act quickly. A legitimate firm will never rush you, and it will always provide verifiable regulatory details. If you cannot confirm a licence number on a public register, do not deposit.

Finally, if you have already sent money, contact your bank or payment provider immediately to attempt a chargeback or recall, and report the firm to your local financial regulator and to the police or cybercrime unit. The sooner you act, the better your chances of recovering funds, though with an unlicensed entity the odds are unfortunately low.

In FXCanary's assessment, JP Morgan Asset Management (CLONE) presents an elevated risk profile that we cannot recommend for any trader. The combination of a misleading name, an unverifiable domain, and a complete absence of regulatory oversight is a pattern we have seen repeatedly in fraudulent and high-risk operations. The Scam Risk Score of 55/100 reflects that pattern, and we see no mitigating factors in the known facts.

We would caution any trader against depositing funds with this entity. The lack of independent reviews is not a neutral fact — it is consistent with a firm that has either not operated long enough to generate a track record or is deliberately avoiding scrutiny. Until verifiable regulatory information is published, the only safe course is to treat this broker as unproven and likely unsafe. We will update this assessment if new evidence emerges, but for now the prudent choice is clear: do not engage.